Menu
Recruiting NCT05112237

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

Observational Cardiomyopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Cardiomyopathy. Basic parameters: 0 years — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Canada, Spain, United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Prospective and Retrospective Registry and Biomarker Study to Evaluate the Natural History of Pediatric Patients With Cardiomyopathy Due to MYBPC3 Mutations

Overview

The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.

Primary outcome measures

  • To characterize the disease course and natural history in participants with pathogenic or likely pathogenic MYBPC3 mutations with a specific focus on cardiac events and measurement [Time frame: 5 years for prospective group, n/a for retrospective group]

Eligibility criteria

Retrospective

Inclusion criteria

  • Data is available for patient <18 years of age. Patients must be <18 years of age at enrollment or at time of death.
  • Documented results of genotyping showing the presence of at least one pathogenic or likely pathogenic MYBPC3 mutation (heterozygous, homozygous, or compound heterozygous).

Exclusion criteria

  • Patient received cardiac transplantation or died >10 years before study initiation. For homozygous or biallelic infants, data may be collected beyond this 10-year period.

Prospective

Inclusion criteria

For Infants:

  • Infants who are homozygous or compound heterozygous for the known pathogenic truncating MYBPC3 mutations are eligible.

For all other participants:

  • Age <18 at entry into the prospective study.
  • Documented results of genotyping identifying at least one pathogenic or likely pathogenic MYBPC3 mutation (heterozygous, homozygous, or compound heterozygous).
  • Diagnosis of Cardiomyopathy (CM): HCM, DCM, RCM, mixed CM, or LVNC.

Exclusion criteria

  • Concurrent participation in an interventional clinical trial unless approved by the sponsor.
  • Severe noncardiac disease anticipated to significantly reduce life expectancy.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

United States · 21 centers
  • Arkansas Children's Hospital — Little Rock
  • Children's Hospital Los Angeles — Los Angeles
  • University of California Davis Health — Sacramento
  • Rady Children's Hospital - San Diego — San Diego
  • University of Colorado Hospital - Anschutz Medical Campus — Aurora
  • Nemours Alfred I. Dupont Hospital for Children — Wilmington
  • Joe DiMaggio Children's Hospital — Hollywood
  • Children's Mercy Hospital Kansas — Kansas City
  • … and 13 more centers
Spain · 3 centers
  • Hospital Sant Joan de Déu Barcelona — Barcelona
  • Hospital General Universitario Gregorio Marañón — Madrid
  • Hospital Alvaro Cunqueiro - Clinico Universitario Vigo — Vigo
United Kingdom · 3 centers
  • NHS Greater Glasgow and Clyde — Glasgow
  • Royal Brompton & Harefield NHS Foundation Trust — London
  • Great Ormond Street Hospital for Children NHS Foundation Trust — London
Canada · 2 centers
  • University of Alberta Hospital — Edmonton
  • The Hospital for Sick Children — Toronto

Identifiers

NCT: NCT05112237 · TN-201-0003

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗